Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Caribou Biosciences (CRBU) Shares Outstanding (2020 - 2025)

Caribou Biosciences has reported Shares Outstanding over the past 6 years, most recently at $95.1 million for Q4 2025.

  • Quarterly Shares Outstanding rose 2.99% to $95.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.1 million through Dec 2025, up 2.99% year-over-year, with the annual reading at $95.1 million for FY2025, 2.99% up from the prior year.
  • Shares Outstanding was $95.1 million for Q4 2025 at Caribou Biosciences, up from $93.5 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $95.1 million in Q4 2025 and troughed at $10.3 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $77.3 million (2023), against an average of $71.4 million.
  • Year-over-year, Shares Outstanding skyrocketed 569.17% in 2021 and then increased 1.04% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $60.3 million in 2021, then rose by 1.27% to $61.0 million in 2022, then skyrocketed by 44.93% to $88.4 million in 2023, then grew by 4.44% to $92.4 million in 2024, then increased by 2.99% to $95.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Shares Outstanding are $95.1 million (Q4 2025), $93.5 million (Q3 2025), and $93.1 million (Q2 2025).